| HOME >> BIOLOGY >> TECHNOLOGY |
TSX symbol: SBS
CALGARY, Oct. 26 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it will be presenting a scientific poster and abstract at the Seventh Annual Diabetes Technology Meeting in San Francisco hosted by the Diabetes Technology Society. The poster will disclose SemBioSys' recent accomplishments in the development of a highly-scalable, low-cost source of recombinant human insulin. Poster session presentations will take place at the San Francisco Airport Hyatt Regency Hotel on Friday, October 26 from 6:00pm to 8:00pm. The poster and abstract are titled:
"Chemical and Biological Characterization of Recombinant Human Insulin Produced in Transgenic Plants," by Joseph Boothe, Cory Nykiforuk, Elizabeth Murray, Philip Kuhlman, W. Brent Pollock, Amanda Bodero, Joseph Goren, Richard Keon, Steven Szarka, Nancy Markley, and Maurice Moloney.
About SemBioSys Genetics Inc. (http://www.sembiosys.com)
Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-l
'/>"/>
| SOURCE SemBioSys Genetics Inc. Copyright©2007 PR Newswire. All rights reserved |